AmpliPhi has just signed a Collaborative Research and Development Agreement (CRADA) with the US Army Medical Research and Development Command and the Walter Reed Army Institute of Research for developing and commercializing phage-based therapies to treat drug-resistant bacterial infections.
Wall Street Journal, July 2013
OmniLytics has relocated from Salt Lake City to Sandy, Utah, US to expand its manufacturing capabilities. In 2010 OmniLytics produced nearly 100,000 litres of bacteriophage product and moving to a site with 60,000 sq ft (from 10,000) of lab and manufacturing space will support continued growth.
Justin Reber, CEO of OmniLytics, said: “This move not only significantly increases our manufacturing capabilities, but also provides the potential for future expansion onto an additional seven acres of undeveloped property acquired adjacent to the four acre, two building campus.”
OmniLytics is also nearing completion of a master plan for the production facility. This will provide equipment to support production of millions of litres of bacteriophage final product a year. May 2011. Source
Old phage site: http://acdrupal.evergreen.edu/phage/ (last update 2009)
Dr. Jason Gill, who for the last several years has been the Program Director at the Center for Phage Technology at Texas A&M, is now taking a faculty position affiliated with the Center in the Department of Animal Science at Texas A&M.